

9 November 2015

## **Appointment of Non-Executive Director**

The Board of Directors of Antisense Therapeutics Limited ('ANP' or the 'Company') is pleased to announce the appointment of Dr Gary Pace as a Non-Executive Director of the Company.

Dr Pace brings a wealth of experience to the ANP Board and has more than 40 years of experience in the development and commercialization of advanced technologies in biotechnology, pharmaceuticals, medical devices and the food industries. He has held senior positions in small to large-scale life sciences ventures and companies in Australia, the USA and Europe. In addition, he has long-term board level experience with both multi-billion and small cap companies. In 2003 Dr Pace was awarded a Centenary Medal by the Australian Government "for service to Australian society in research and development", and in 2011 was awarded Director of the Year (corporate governance) by the San Diego Directors Forum.

Dr Pace is currently a Director of three other public companies; ResMed (ASX/NYSE, RMD); Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) and Transition Therapeutics Inc. (NASDAQ: TTHI), as well as several private companies. He has also previously held directorships in other ASX listed biotechnology companies including Peplin Ltd. which was successfully sold to Leo Pharmaceuticals for US\$290M in 2009.

Dr Pace holds a B.Sc. (Hons I) from the University of New South Wales and a PhD from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. He has authored or co-authored over 50 research and review papers, has been awarded 24 patents. In addition he has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering.

In welcoming Dr Pace to the Board, Antisense Therapeutics Chairman Bob Moses said "In our search for another non-executive director as part of our previously signalled Board renewal plans, we looked for a person with exceptional senior level experience in developing high technology companies as well as a person having an intimate understanding of, and credibility with relevant industry and investment networks in the United States as well as in Australia. Dr Pace is the perfect complement to our Board and our other recently appointed US-based non-executive director, Bill Goolsbee, who together will enhance ANP's strategic positioning and representation in the States."

Dr Pace added "Antisense represents an exciting opportunity. I look forward to working with the Board and Staff of Antisense and to bringing my expertise, experience and global networks in life sciences to increase shareholders' value."

Dr Pace's appointment is effective immediately and will be confirmed after the 2015 Annual General Meeting.

*Contact Information:*

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director – Mark Diamond +61 3 9827 8999